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Background: The microbiological procedures for cystic fibrosis (CF) samples of 17 participating Spanish centers were
examined to verify their compliance with current international and national guidelines and to implement the best
standards of care for microbiology practices. A 47-item questionnaire covering different CF microbiology aspects was
sent to participant laboratories. Telephone interviews were performed when necessary. Data about samples processing
for bacteria, mycobacteria and fungi were collected.
Results: Gene sequencing (71%), MALDI-TOF (59%) or both (94%) were available for most laboratories. Susceptibility
testing was performed by automated microdilution systems (94%) and manual diffusion methods (59%). However,
a low use of selective media for Staphylococcus aureus (59%) and Burkholderia cepacia complex (71%), and of
epidemiological typing methods (41%) was reported.
Conclusions: Most Spanish laboratories are in agreement with consensus guidelines for the processing of CF
respiratory samples, but need to improve in the use of specific selective media and typing methods for
epidemiologic studies.
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Cystic fibrosis (CF) disease is produced by mutations in the
CF transmembrane conductance regulator gene (CFTR).
Altered CFTR leads to the production of viscous secretions
in respiratory airways that cannot be cleared by the muco-
ciliary system and patients get chronically colonized by dif-
ferent microorganisms (bacteria, mycobacteria and fungi)
which cause inflammation, progressive lung destruction
and, finally, death by respiratory failure [1].
Microbiological diagnosis of CF has evolved far be-
yond the isolation and identification of classic pathogens
such as Pseudomonas aeruginosa and Staphylococcus
aureus [2]. Early diagnosis of CF disease and better strat-
egies of patient management have substantially increased* Correspondence: rafael.canton@salud.madrid.org
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unless otherwise stated.patients’ life expectancy with a subsequent impact on CF
pathogens epidemiology [2,3]. Continuous follow-up of
microbial colonization represents a challenge to clinical
laboratories for its complexity and has become a stand-
ard of care in patient management. Recommendations
for the CF microbiology laboratory management have
been included in the European Cystic Fibrosis Society
(ECFS) guidelines, as part of the framework of a special-
ized CF center [4,5].
High antibiotic pressure and the special environment of
the CF lung allow the establishment of multi-drug resis-
tant bacteria that require special techniques for their isola-
tion and/or identification, such as Burkholderia cepacia
complex (BCC), other non-fermenting Gram negative
rods (NFGNR) and nontuberculous-mycobacteria (NTM)
[2,3]. In addition, commonly isolated pathogens such as P.
aeruginosa or S. aureus can exhibit altered phenotypic
characteristics as a result of time-dependent adaptiveal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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colony variants (SCVs) and hyper-mutable and mucoid
strains variants. Correct diagnosis of these phenotypic var-
iants is difficult and has clinical relevance as there is grow-
ing evidence that correlates them with multi-drug
resistance, persistency phenomena and poorer lung func-
tion [6-9]. Moreover, accurate isolation, identification and
susceptibility testing of CF pathogens are critical for en-
suring appropriate treatment and implementation of in-
fection control measures, and also for improving our
understanding of CF microbiology [10-14].
Laboratories working with CF samples need special
procedures and installations as well as specialized micro-
biologists to provide a correct patient assessment for cli-
nicians [4,10-14]. Adherence to consensus guidelines is
also important for laboratories to obtain comparable re-
sults and for their adaptation to the best standards of
care in CF patients [4,10,14]. The aim of this work was
to compile information about the microbiological proce-
dures of the Spanish Hospitals with CF Units in order to
assess their compliance with recent consensus guidelines




Seventeen hospital microbiology laboratories covering all
the Spanish territory were requested to participate byTable 1 Characteristics of the Spanish hospitals participating
Geographical area Hospital name Popu
atte
Madrid Ramón y Cajal 550




Asturias Central de Asturias 500
Basque Country Cruces 384
Catalonia Parc Tauli 394
San Joan de Déu 200
Vall d’Hebrón 453
Balearic Islands Son Espases 330
Valencian Community La Fe 198
Clínico de Valencia 350
Region of Murcia Virgen de la Arrixaca 254
Andalusia Vigen del Rocío 820
Hospital Regional de Málaga 623
Canary Islands Nuestra Señora de la Candelaria 700
TOTAL 7,14answering to our questionnaire (Table 1) and all of them
agreed. These centers, which are reference CF Units in
their corresponding geographic areas, were selected due
to their collaboration with us in another multicenter
study focused on CF microbial colonization patterns. Al-
though the precise number of CF patients in our country
is unknown since no national patient registry exists, cen-
ters included in this survey attend to the majority of the
Spanish CF population. The total population attended by
these hospitals is approximately 7,150,000 people (mean
420,502). The total number of hospital beds is 15,183
(mean 893) and 1,037 (mean 61) for intensive care units
(ICU). The number of CF patients attended by these
centers is 2,315 (Table 1), which represents 75% of the
CF Spanish population according with the last ECFS re-
port [15].
The number of CF samples processed weekly by each
laboratory varies from 10 to 20 in the majority of cases
(n = 7, 41%, Figure 1). Only 5 laboratories (29.4%) have a
CF section exclusively dedicated for the CF samples pro-
cessing, although in all cases the final report to clinicians
was under the responsibility of a clinical microbiologist.
Sixteen laboratories (94%) have written protocols for
processing CF samples. More than half are certified by a
Quality Management System (n = 10, 58.8%), the most
commonly implemented being ISO9001 (n = 8; 80%)
followed by other national or regional systems (n = 2;
20%). All laboratories follow a periodical external qualityin the study
lation
nded
Number of beds Number of CF patients
Total ICU
,000 1,100 60 150
,252 1,300 96 208
,000 1,200 67 151
,000 564 22 87
,000 180 14 85
,000 1,000 50 51
,000 865 24 209
,000 714 30 75
,000 300 44 55
,196 1,146 182 175
,000 1,020 107 40
,889 980 100 344
,000 500 20 40
,000 900 58 130
,904 1,367 62 360
,301 1,147 61 105
,000 900 40 50
8,542 15,183 1,037 2,315
Figure 1 CF samples processed weekly by participant laboratories.
Table 2 Culture media used for the isolation of CF
pathogens
Culture medium N° of laboratories using media (%)
Bacteria 17 (100)
• Columbia blood agara 17 (100)
• Chocolate agarb 17 (100)
• MacConkey agar 17 (100)
Selective media for:
• S. aureusc 10 (59)
• P. aeruginosa 0 (0)
• BCC 12 (71)
Mycobacteria:d 15 (88)
• Lowenstein-Jensene 8 (53)
• Coletsos 3 (20)
• Liquid enrichment media 14 (93)
Fungi:f 17 (100)
• Sabouraud agarg 17 (100)
aBlood agar alone (n = 16) or supplemented with nalidixic acid (n = 3).
bChocolate agar alone (n = 16) or supplemented with bacitracin plus colistin
(n = 3) or with bacitracin plus amphotericin B (n = 1).
cMannitol salt agar (n = 7), Columbia blood agar plus nalidixic acid (n = 3) and
chromogenic agar (n = 2).
d15 out of 17 laboratories answered this question.
eLowenstein-Jensen alone (n = 2) or supplemented with antibiotics (n = 6) or
piruvate (n = 1).
fBoth yeasts and filamentous fungi.
gSabouraud-Chloramphenicol agar alone (n = 13) or supplemented with genta-
micin (n = 2) or actidione (n = 1).
BCC: Burkholderia cepacia complex.
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Infectious Diseases and Clinical Microbiology (SEIMC,
www.seimc.org) in all cases.
CF samples processing
Spontaneous sputum was reported as a very frequent or
a frequent sample in 94% and 6% of the centers and
nasopharyngeal swabs in 29% and 41%, respectively. In-
duced sputum, bronchoalveolar lavage and bronchoaspi-
rate were very infrequent or absent in 77%, 65% and
65% of the centers, respectively.
Initial homogenization of sputum for bacterial and fun-
gal culture was performed by nearly all laboratories (n =
16, 94%), N-acetylcysteine (NAC) and dithiothreitol being
the most common chemical agents used (n = 11, 65% and
n = 4, 23.5%; respectively). Samples pretreatment for
NTM culture was reported by 13 laboratories; the com-
bination of NAC plus 2% NaOH being the preferred op-
tion (Kubica-Krasnow method; n = 11), followed by the
combination of 3% sodium lauryl sulphate plus 1% NaOH
(Tacquet-Tison method; n = 2).
Quantitative culture for bacterial pathogens was rou-
tinely carried out by only 14 laboratories (82%), using
calibrated loops (n = 7) or serial dilutions plus whole
plate seeding (n = 7). Fungal CF colonizers were cultured
routinely in 13 centers and on the clinician’s request in
4. NTM culture of CF samples was reported in 15 (88%)
laboratories. Anaerobic bacteria in CF samples were
never considered as relevant in 14 centers and cultured
in 3 laboratories only under clinician’s request.Isolation, identification and antibiotic susceptibility
testing of CF pathogens
The use of culture media for bacterial, mycobacterial
and fungal pathogens is shown in Table 2. Columbia
blood agar, chocolate agar and MacConkey agar were
universally used but selective media for S. aureus and
BCC were not present in all laboratories (59% and 71%,
respectively). For culturing NTM, automated systems
with liquid enrichment media were the most frequently
used (n = 14; 93%). Sabouraud-chloramphenicol agar was
universally used for culturing fungi.
Identification techniques used by the clinical labora-
tories are shown in Table 3. Traditional procedures, in-
cluding biochemical tests or microscopy (for filamentous
fungi), were widely used for determining bacterial and
fungal species. The main techniques for identification of
NTM were hybridization assays (n = 13) followed by bio-
chemical tests (n = 9). For in depth identification of bac-
teria, mycobacteria and fungi, use of gene sequencing
was reported in 12 (71%), 9 (53%) and 10 (59%) labora-
tories, respectively. The corresponding figures for mass
spectrometry were 10 (59%), 9 (53%) and 8 (47%), re-
spectively. Nearly all centers (n = 16, 94%) had at least
one of both techniques.
Table 3 Identification techniques used in CF clinical microbiology laboratories no. (%)
Bacteria Mycobacteria Yeasts Filamentous fungi
BCT 17 (100) 9 (53) 8 (47) 9 (53)
Agglutination assays 17 (100) - - -
SFT - - 11 (65) -
Microscopy - - - 15 (88)
MALDI-TOF 10 (59) 9 (53) 8 (47) 8 (47)
PCR + sequencing
rDNAa 11 (65)c 8 (47)d 6 (35)e 6 (35)f
ITS region - - 7 (41)e 8 (47)f
Othersb 5 (29)c - - -
Hybridization assays - 14 (82) - -
RFLPs - 3 (18)d - -
BCT: Biochemical tests; SFT: serum filamentation tests. RFLPs: Restriction Fragment Length Polymorphisms.
a16S rDNA in the case of bacteria and 18S rDNA in the case of fungi.
brecA gene, hsp65 gene, etc.
c4 centers reported the use of >1 technique.
d3 centers reported the use of both techniques.
e, f4 centers reported the use of both techniques.
Table 4 Information reported to clinicians for CF samples
Information included in the laboratory report No. of
centers (%)
Isolated species 17 (100)
Antibiotic susceptibility 17 (100)
Use of different MIC interpretation for inhaled antibioticsa 5 (29)
Total count of microorganisms 3 (18)
Individual count of each species 11 (65)
P. aeruginosa morphotype 16 (94)
P. aeruginosa hypermutable trait 4 (24)
S. aureus SCVs 4 (24)
MICs: Minimal inhibitory concentrations; SCVs: Small-colony variants.
aInhaled tobramycin breakpoints for P. aeruginosa: Susceptible (≤64 μg/mL) or
resistant (>64 μg/mL).
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gens was performed by all participant laboratories. Most
of them reported the use of automated microdilution
systems (n = 16) and agar diffusion techniques, either
disk diffusion (n = 2) or gradient strips (Etest®, n = 4), or
both (n = 10). Automated systems were MicroScan (n =
8), VITEK2 (n = 3) or both (n = 5).
Antifungal susceptibility is routinely evaluated in 2
(12%) centers and under special conditions in 8 (47%)
which include clinician’s request (n = 4), clinically signifi-
cant isolates (n = 2), treatment refractory cases (n = 2),
isolation of Scedosporium spp. (n = 1) and pre-transplant
patient status (n = 1). Susceptibility assays are performed
by broth microdilution (n = 3), agar diffusion with anti-
fungal gradient strips (Etest®, n = 3) or both (n = 4).
Most laboratories (n = 11) report culture results in 3–5
days and the rest in 1–3 days (n = 5) or >5 days (n = 1).
Information sent to clinicians of bacterial culture is
summarized in Table 4.
Clonal relationships between strains for epidemio-
logical studies were performed in 7 (41%) laboratories,
the pulse field gel electrophoresis (PFGE) being the main
technique used, alone (n = 3) or in combination with
multi-locus sequence typing (MLST) (n = 4).
Discussion
A correct processing of CF samples is critical to identify
the maximum number of potential pathogens in the res-
piratory airways. Incorrect results in the isolation, identi-
fication and susceptibility testing of CF organisms have
negative consequences in the patient’s clinical manage-
ment and quality of life, and can affect the whole CF
community by delaying the implementation ofappropriate infection control measures to prevent
patient-to-patient transmission [10-14,16-18]. Patho-
gens with known clinical and epidemiological import-
ance, such as P. aeruginosa, S. aureus or BCC, could be
misidentified due to their phenotypic variation or to the
limitations of the classical culture techniques with these
organisms [6,18]. Less known pathogens, such as non-P.
aeruginosa NFGNR, filamentous fungi, certain yeasts and
NTM, could also be missed. Standardized microbio-
logical procedures could help to avoid this situation and
to better understand its clinical and epidemiological im-
portance. The present work is an overview of the pro-
ceedings of the main CF Spanish laboratories that might
be used to improve the clinical microbiological proce-
dures in line with current guidelines and with the recom-
mendations of standards of care from the European
Cystic Fibrosis Society [4,5,10,14].
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procedures of the Microbiology Laboratory [18]. It requires
the use of different media and the identification and sus-
ceptibility testing of multiple isolates per patient, employ-
ing techniques that are more complex than those used for
non-CF samples, and with difficult to interpret results. In
our study, only 5 laboratories have an individual section
within the Microbiology Department dedicated to CF.
Even thought a clinical microbiology specialist is always
responsible for the results, potentially assuring better
compliance with the currently recommended framework
for CF centers [4], the presence of experienced personnel
is critical to recognize and isolate all the specific CF path-
ogens and their phenotypic variants [4]. Prolonged incu-
bation times are also needed for the isolation of these
variants and of BCC species [10,14,18]. However, most of
the laboratories reported culture results in less than 5 days,
which might be insufficient for these pathogens. A positive
result is that all laboratories participate in external quality
assurance programs which are crucial to evaluate and con-
tinuously improve the quality of the laboratory perform-
ance [4]. Unfortunately, there are no specific quality
assurance programs for CF in our country. The imple-
mentation of these programs, using multiple CF patho-
gens and phenotypic variants, would be desirable for a
correct evaluation of the CF laboratory [17].
Almost all laboratories homogenize sputum with mu-
colytic agents as currently recommended for the more
viscous CF airways secretions, in which microorganisms
grow as biofilm-like microcolonies [14,17]. However,
quantitative culture using serial sample dilutions were
not performed in all centers. This explains why few la-
boratories report individual bacteria counts (68%) and
even fewer total bacterial load (18%). Although the clin-
ical value of quantitative culture is controversial, it is a
useful practice as it permits an efficient separation of
different CF pathogens and their phenotypic variants
even when present in low densities, preventing the
overgrowth of P. aeruginosa. Moreover, it can also serve
for monitoring treatment efficacy [14,17].
While all laboratories report the presence of mucoid
P. aeruginosa morphotype to clinicians, few of them
(24%) inform about hyper-mutable traits or SCVs of P.
aeruginosa or S. aureus isolates. These variants could
modify treatment strategies as they are related to anti-
biotic resistance and persistency, so informing clini-
cians about their presence could be clinically and
epidemiologically important [6-9]. Performing quantita-
tive cultures and using selective and chromogenic
media, along with prolonged incubation times can help
in the detection of SCVs. There are several methods
described to identify hyper-mutable strains, although
the observation of microcolonies within the inhibition
zones when using disk diffusion and/or MIC strips forsusceptibility testing is probably the easiest method for
this objective [10,14,19].
American, European and Spanish CF guidelines strongly
recommend selective media for the isolation of S. aureus,
P. aeruginosa, BCC and Haemophilus influenzae
[10,14,20]. While all laboratories use MacConkey and
chocolate agars for the P. aeruginosa and H. influenzae
isolation, not all of them use specific selective media
for S. aureus (59%) and BCC (71%). These rates are
considerably low when compared with the correspond-
ing figures in Germany (69% and 91%, respectively) and
USA (82% and 99%, respectively) [12,13]. Lack of these
media is associated with lower isolation rates of these
organisms, which are difficult to identify in the CF con-
text and that can be easily obscured by the overgrowth of
P. aeruginosa. Missing pathogens like BCC or methicillin-
resistant S. aureus (MRSA) is especially worrisome since it
could have an impact not only at patient level but affect-
ing also the whole CF community by patient-to-patient
transmission [10,11,18]. A very positive result of the study
is that nearly all laboratories have molecular and/or mass
spectrometry assays for the identification of CF pathogens.
Conventional biochemical tests, including those in auto-
mated systems, often give false identification results for
NFGNR and phenotypic variants of P. aeruginosa, and are
unreliable for identifying single species of the BCC
[13,17,18,21]. PCR based techniques are recommended
for the identification of these pathogens and can serve also
for BCC [14]. However, mass spectrometry is a rapid,
cheaper and a reliable alternative to PCR for these organ-
isms, and is also a promising tool for mycobacteria and
fungi [22-25].
Another positive result of the study is the use in nearly
all laboratories of agar diffusion tests in addition to auto-
mated microdilution systems for antimicrobial suscepti-
bility testing. Use of both techniques is especially
relevant. Automated microdilution systems alone are not
recommended for P. aeruginosa due to unacceptable
major (false resistance) and very major (false susceptibil-
ity) errors [10,14]. On the contrary, disk diffusion and
gradient strips correlate better with reference methods
and have the advantages of detecting hyper-mutable var-
iants and, in the case of gradient strips, the use of a
wider range of concentrations allows to the application
of proposed breakpoints for inhaled therapy [14,26].
S. aureus, including MRSA, P. aeruginosa and BCC
are pathogens with a proved spreading between CF pa-
tients but patient-to-patient transmission of S. maltophi-
lia, A. xylosoxidans and NTM has also been suggested
[10,27,28]. However, only 7 (41%) laboratories reported
the use of PFGE or MLST techniques for routine epide-
miologic studies and none of them reported the use of
next generation sequencing procedures that are being
increasingly introduced in clinical laboratories.
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during the last years and has been recently estimated as
10% of all CF patients, Mycobacterium avium complex
and M. abscessus being the most commonly isolated [29].
The only recommendation for culturing NTM is an ad-
equate pretreatment of CF samples to minimize culture
contamination by P. aeruginosa [10,14]. Most Spanish la-
boratories perform the Kubica-Krasnow method with
NAC plus 2% NaOH. Consensus guidelines recommend a
second decontamination step with 5% oxalic acid to re-
duce contaminations with P. aeruginosa [10,14]. Recently,
a more sensitive method using chlorhexidine has been de-
scribed but it interferes with the automated liquid enrich-
ment media culture systems [10,30].
Although CF consensus guidelines also recommend fun-
gal cultures [4,10,14], no specific information is provided
about the best procedures in this setting. While all
Spanish laboratories use Sabouraud-Chloramphenicol agar,
better results have been achieved using selective media for
CF fungal colonizers, suggesting that the prevalence of
these organisms has been probably underestimated in CF
[31,32]. Protocols for culturing fungi are, therefore, needed
to elucidate their possible role in CF pathogenesis.
In our study few laboratories cultured respiratory samples
under anaerobic conditions. Currently, there are no specific
recommendations for this practice in CF samples. However,
recent microbiome studies suggested a possible role of
these organisms, especially Prevotella spp. [2]. Since isola-
tion, identification and susceptibility testing techniques for
these organisms are difficult to perform, next generation
systems and metagenomic tools would probably be the pre-
ferred option to study the role of these bacteria in CF [2].
Conclusions
In summary, there are few studies regarding the assess-
ment of microbiological procedures in CF samples and
this is the first one performed in our country [12,13,17].
The results show that Spanish CF laboratories are gener-
ally in agreement with National, European and American
consensus CF guidelines. However, certain procedures
should be improved, such as creation of specific CF sec-
tions within the laboratory, inclusion of selective media
for S. aureus and BCC and implementation of typing
methods for epidemiologic studies. These actions will fa-
cilitate Spanish CF microbiology laboratories to be in
line with recommended standards of care for Microbiol-
ogy laboratories within the framework of European CF
centers [4]. Moreover, this alignment will improve
microbiological diagnosis and, subsequently, patient’s
treatment, management and quality of life.
Methods
A questionnaire for the participating laboratories was
elaborated based on the recommendations for themicrobiological diagnosis of bronchopulmonary infec-
tion in CF patients published by the Spanish Society of
Clinical Microbiology and Infectious Diseases (SEIMC),
by the Cystic Fibrosis Foundation, and those included in
National and International Guidelines for the manage-
ment and treatment of CF patients [4,10,14,17]. It was a
47 questions document that was divided in three sec-
tions: i) general information about the hospital and the
clinical microbiology laboratory; ii) general processing of
CF samples and iii) isolation, identification and suscepti-
bility testing techniques used for bacterial, mycobac-
terial and fungal CF pathogens (see Additional file 1).
An online survey tool (SurveyMonkey Inc; Palo Alto,
California, EEUU; www.surveymonkey.com) was used for
sending the questionnaire to the participating laborator-
ies and for analyzing the data obtained. Telephone inter-
views were performed when necessary to clarify specific
answers to the questionnaire. This work was part of a
multicenter study which was approved by Ramón y Cajal
Hospital Clinical Research Ethical Committee (reference
n° 341/12).
Additional file
Additional file 1: Cystic Fibrosis Microbiology Questionnaire. A PDF
file of an English translated copy of the 47-intem questionnaire sent to
the participant laboratories was included.
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